<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03951337</url>
  </required_header>
  <id_info>
    <org_study_id>ICO-N-2017-14</org_study_id>
    <nct_id>NCT03951337</nct_id>
  </id_info>
  <brief_title>64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)</brief_title>
  <official_title>Evaluation of 64Cu-ATSM PET/CT in Predicting Neo Adjuvant Treatment Response in Locally Advanced Rectum Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Cancerologie de l'Ouest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation ARC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Cancerologie de l'Ouest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is assessing how 64Cu-ATSM (64Cu-copper(II)
      diacetylbis(N4-methylthiosemicarbazone)) PET/CT scan could predict neo adjuvant treatment
      response in rectum cancer locally advanced
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate early and late tumor uptake of 64Cu-ATSM in
      predicting histological response to neo-adjuvant chemo-radiotherapy treatment in patients
      with locally advanced rectal cancer.

      Patients receive pre-therapeutic CT scan, Pelvic MRI and 18FDG (fluorodeoxyglucose) PET/CT
      (positron emission tomography) scan within 45 days before enrollment.

      64Cu-ATSM PET/CT scan is done before chemoradiotherapy treatment start. About 3 MBq/Kg of
      64Cu-ATSM are injected intravenously, two acquisition sequences are performed 1 hour and 23
      to 25 hours after injection in order to evaluate early and late tumor uptake of 64Cu-ATSM.

      Patients are treated for 5 weeks by Capecitabine chemotherapy (1600 mg/m2/day) combined to 50
      Gy radiotherapy.

      Pelvic MRI is performed 4 weeks after chemotherapy in order to evaluate the treatment
      efficacy.

      Surgery is scheduled 6 to 8 weeks after chemoradiotherapy. Tissue samples from previously
      collected rectal biopsy (obtained for diagnosis) and from surgery are used for assessing
      oxidative stress markers by Immuno-histochemical analysis.

      Chest, abdomen and pelvis CT scan is performed every 6 months after surgery in order to
      assess progression free survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicentric, open prospective study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship between early tumor uptake of 64Cu-ATSM PET/CT images and prediction of histological response to neo-adjuvant chemo-radiotherapy treatment</measure>
    <time_frame>4 months</time_frame>
    <description>Early tumor uptake of 64Cu-ATSM will be assessed by SUV (Standardized Uptake Value) measurement, histological response Will be assessed by Rodel grading (Tumor Regression Grading)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between late tumor uptake of 64Cu-ATSM PET/CT images and prediction of histological response to neo-adjuvant chemo-radiotherapy treatment</measure>
    <time_frame>4 months</time_frame>
    <description>Late tumor uptake of 64Cu-ATSM will be assessed by SUV (Standardized Uptake Value) measurement, histological response Will be assessed by Rodel grading (Tumor Regression Grading)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between 64Cu-ATSM uptake and oxidative stress markers</measure>
    <time_frame>4 months</time_frame>
    <description>Aggressive zones corresponding to high redox potential areas will be assessed by Immuno-histochemical analysis on the surgical sample and on the pre-therapeutic biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Progression Free survival is the delay between surgery and the date of documented disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>18FDG-PET/CT and 64Cu-PET/CT uptakes</measure>
    <time_frame>45 days</time_frame>
    <description>Correlation between 18FDG-PET/CT and 64Cu-PET/CT uptakes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between early and late 64Cu-ATSM uptakes in 64Cu-ATSM PET/CT images</measure>
    <time_frame>45 days</time_frame>
    <description>Early and Late tumor uptake of 64Cu-ATSM will be assessed by SUV (Standardized Uptake Value) measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>64Cu-ATSM toxicity</measure>
    <time_frame>45 days</time_frame>
    <description>64Cu-ATSM toxicity will be assessed by vital signs monitoring within 2 hours after 64Cu-ATSM injection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>64Cu ATSM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pretherapeutic 64Cu-ATSM PET/CT scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>64Cu-ATSM</intervention_name>
    <description>64 Cu-ATSM PET/CT scan</description>
    <arm_group_label>64Cu ATSM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed rectum adenocarcinoma

          -  Locally advanced, non metastatic disease, with or without locoregional lymph node
             involvement (greater than or equal to T3 +/- N), first-line therapy

          -  18 Years and older

          -  Performance Status equal to 0 or 1

          -  Fertile patients must use effective contraception

          -  Hemoglobin greater than 9g/dl, neutrophils greater than 1 500/mm3, platelets greater
             than 100 000/mm3

          -  Creatinine clearance greater than or equal to 50ml/min

          -  Plan to receive treatment with concurrent chemotherapy and radiation therapy followed
             by surgery

          -  Totality of the tumor included in the radiotherapy field

          -  Written informed consent

          -  Patient must be affiliated to a Social Health Insurance

        Exclusion Criteria:

          -  metastatic disease

          -  Patient contraindicated for capecitabine or 5FU (5-Fluoro-Uracile) derivatives
             (history of severe and unexpected reactions to fluoropyrimidine-containing therapy,
             known hypersensitivity to 5FU, to any of the excipients, or known total DPD
             (dihydropyrimidine déshydrogénase) deficiency)

          -  Known Contraindication to perform MRI

          -  Previous treatment with pelvic radiotherapy

          -  Chronic inflammatory bowel disease, malabsorption, lack of colonic integrity

          -  Diarrhea grade greater than 2

          -  Contraindication to surgery

          -  Bilateral total hip prosthesis

          -  Other malignancy treated within the last 5 years (except non-melanoma skin cancer or
             in situ carcinoma of the cervix)

          -  Pregnant or nursing patient

          -  Individual deprived of liberty or placed under the authority of a tutor

          -  Impossibility to submit to the medical follow-up of this clinical trial for
             geographical, social or psychological reasons

          -  Agitation; impossibility of lying motionless for at least 1 hour, or known
             claustrophobia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathilde COLOMBIE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancerologie de l'Ouest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathilde COLOMBIE, MD</last_name>
    <phone>+33240679900</phone>
    <phone_ext>9501</phone_ext>
    <email>mathilde.colombie@ico.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nadia FLEURY, PhD</last_name>
    <phone>+33240679900</phone>
    <phone_ext>9168</phone_ext>
    <email>nadia.fleury@ico.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancerologie de l'Ouest (ICO)</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde COLOMBIE, MD</last_name>
      <phone>+33240679900</phone>
      <phone_ext>9501</phone_ext>
      <email>mathilde.colombie@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Mathilde COLOMBIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de BREST</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Yves SALAUN, MD, PhD</last_name>
      <phone>+33298223117</phone>
      <email>pierre-yves.salaun@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Yves SALAUN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35045</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne DEVILLERS, MD</last_name>
      <phone>+33299253084</phone>
      <email>a.devillers@rennes.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Anne DEVILLERS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancerologie de l'Ouest</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathilde COLOMBIE, MD</last_name>
      <phone>+33240679900</phone>
      <phone_ext>9501</phone_ext>
      <email>mathilde.colombie@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Mathilde COLOMBIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>64Cu-ATSM</keyword>
  <keyword>neoadjuvant treatment</keyword>
  <keyword>chemoradiotherapy</keyword>
  <keyword>surgery</keyword>
  <keyword>Positron Emission Tomography (PET)/CT scan</keyword>
  <keyword>Prediction of response to treatment</keyword>
  <keyword>Rodel score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

